Drugs / H5N8 antigen
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06560151 | Aug 2024 → Jan 2025 | influenza | Biomedical Advanced Research and Development Authority | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5N8 antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06560151 ↗ |
| Known as | Egg-A/Astrakhan/3212/2020 (H5N8) | “This treatment group of 60 participants (ages 18-64) in Treatment Group A will receive 3.75 µg of Egg-A/Astrakhan/3212/2020 (H5N8) antigen adjuvanted with a full dose of AS03A.” NCT06560151 ↗ |
| Modality | Vaccine | “A/H5 inactivated monovalent influenza vaccines” NCT06560151 ↗ |
| Route | Intramuscular | “Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.” NCT06560151 ↗ |